The World Health Organization validated that Eritrea has eliminated trachoma as a public health problem, the agency reported. This recognition makes Eritrea the 11th country in WHO’s African Region and the 34th globally to reach validation status. WHO Director-General Dr Tedros Adhanom Ghebreyesus congratulated the Government and communities on achieving this target after “two decades of determined effort,” the organisation stated. The announcement frames elimination as an outcome of sustained national commitment and community engagement.
Eritrea scaled the WHO-recommended SAFE strategy—surgery for trachomatous trichiasis, antibiotics to clear infection, facial cleanliness, and environmental improvements—in areas identified as endemic. National baseline surveys conducted between 2006 and 2020 provided the epidemiological basis for action, the source reported. The country surveyed all 58 sub-zobas (second-level administrative areas) and expanded interventions in districts where trachoma persisted. The article did not provide specific clinical dosing schedules or the number of antibiotic rounds applied in each district.
WHO materials linked to the announcement explained that repeated infection with Chlamydia trachomatis can scar the inner eyelid and cause trichiasis, a condition that may lead to blindness. Eritrea’s programme focused on the combination of surgical management for advanced cases and community-level measures to reduce transmission.
Health workers in Eritrea reportedly employed digital tools for data collection and mapping to locate affected communities, including hard-to-reach areas. The programme adopted a community-led sanitation approach that, according to WHO, produced public health gains with limited external funding. The source credited collaboration among communities, the Ministry of Health, the Fred Hollows Foundation, development partners and health workers for operational success. WHO noted it provided support throughout the country’s elimination efforts and will continue engagement to help sustain gains.
The announcement states that antibiotics delivered during Eritrea’s programme were predominantly oral azithromycin, donated through Pfizer Inc. via the International Trachoma Initiative. The WHO release did not include detailed information on dosing regimens, coverage percentages, or the timeline for mass drug administration. Eritrea has established systems to identify and manage new trichiasis cases and will maintain surveillance after validation, the source said.
WHO validation follows an independent review process. A WHO-appointed dossier review group examines the evidence submitted by a country and confirms that agreed epidemiological thresholds have been met and that systems exist to detect and manage future cases. WHO’s announcement made clear that validation provides independent confirmation that the criteria for eliminating trachoma as a public health problem have been achieved.
The source specified that Eritrea will continue surveillance and maintain systems to detect and treat any new trichiasis cases. The announcement did not detail the specific surveillance indicators, frequency of surveys, or thresholds that will trigger programmatic response post-validation.
WHO placed Eritrea’s achievement in a broader global context: the population estimated to require interventions against trachoma fell from about 1.5 billion in 2002 to below 100 million by November 2025. Despite that reduction, the organisation reported that as of March 2026 some 92 million people still lived in trachoma-endemic areas and remained at risk of blindness. The source added that trachoma continued to be a public health problem in parts of 29 countries.
In 2025, WHO data reported that 98,829 people received surgery for advanced trichiasis and 47.4 million people received antibiotics globally. Eritrea’s validation also contributed to the broader neglected tropical diseases (NTD) agenda: the country became the 66th globally and the 23rd in the African Region to eliminate at least one NTD, according to WHO.
Limitations and outstanding questions
The WHO news release did not provide program-level operational metrics such as intervention coverage by year, exact antibiotic dosing schedules, cost or financing breakdowns, or specific post-validation surveillance performance indicators. It also did not specify the timeframe for maintaining active case-finding systems or the thresholds that would prompt renewed mass interventions. These gaps represent concrete information needs for program managers and partners planning sustained surveillance and potential response activities in the post-validation period.
The announcement closed with WHO pledging continued support to the Government of Eritrea and partners to sustain the gains against trachoma and to manage any future cases.